<DOC>
	<DOCNO>NCT03010761</DOCNO>
	<brief_summary>No medication exist BQ dependence . No clinical trial exist drug therapy . Previous study show BQ possess antidepressant effect via pathway monoamine oxidase A ( MAO-A ) . An animal model also find arecoline BQ property MAO-A inhibitor . Therefore , investigator hypothesize inhibition MAO-A antidepressant might reduce BQ addiction severity . The investigator conduct randomization double blind placebo control study 90 participant BQ dependence Family Medicine ear , nose , throat ( ENT ) outpatient department ( OPD ) . All participant shall agree informed consent . The range age 18 65 year old . The participant diagnose BQ use disorder without psychiatry co-morbidity , accord Diagnostic Statistical Manual ( DSM ) -V criterion . Those severe physical illness , psychiatric illness , substance use disorder except cigarette exclude . All participant receive semi-structure interview DSM-V , International Classification Diseases ( ICD ) -10 , Mini International Neuropsychiatric Interview psychiatrist . Before intervention , participant finish basic data , daily amount cigarette , betel nut , medical history psycho-social rating scale . Next , addition counseling , investigator continue modify optimal antidepressant base previous result . The investigator evaluate BQ use condition measure natural observation study first year . The investigator check outcome measurement visual analog scale , betel quid withdrawal severity scale , Yale-Brown Obsessive-Compulsive ( Y-BOCS ) - betel quid ( BQ ) scale . The investigator also follow hamilton depression scale ; Beck depression index ; Beck anxiety index baseline , 2nd , 4th , 6th , 8th week . The investigator also obtain participant ' gene type participant also agree prediction oral cancer .</brief_summary>
	<brief_title>Establishment Cessation Therapy Clinical Trials Subjects With Betel-quid Dependence Oral Pre-cancer</brief_title>
	<detailed_description>We 'll conduct betel-quid ( BQ ) dependence clinical trial since 2016 . Eligible case enrol follow 8 week double-blinded placebo control trial . The group divide three group . Outcome measure include BQ use condition , addiction severity rating scale , emotional rating scale include Beck Anxiety Index ( BAI ) , Beck Depression Index ( BDI ) , Hamilton Depression Scales ( HAMDs ) , urine BQ metabolite .</detailed_description>
	<mesh_term>Behavior , Addictive</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Moclobemide</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>DSMV criterion suitable betelnut use disorder No severe physical disorder No major psychiatric illness Chinese Speaker Severe physical disorder Major psychiatric illness Inability understand whole protocol</criteria>
	<gender>Male</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>addiction</keyword>
	<keyword>betel-quid</keyword>
	<keyword>drug therapy</keyword>
	<keyword>clinical trial</keyword>
</DOC>